PepGen (PEPG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting will be held virtually on June 18, 2026, with voting on director elections and auditor ratification.
Proxy materials are distributed electronically to reduce costs and environmental impact.
Only stockholders of record as of April 21, 2026, are eligible to vote.
The company remains an emerging growth company and provides scaled disclosures under the JOBS Act.
Voting matters and shareholder proposals
Stockholders will vote on electing three Class I directors for three-year terms and ratifying KPMG LLP as the independent auditor for 2026.
Board recommends voting FOR all director nominees and auditor ratification.
Shareholders may submit proposals for the 2027 meeting between February 18, 2027, and March 20, 2027.
Proposals for inclusion in the 2027 proxy must be received by December 30, 2026.
Board of directors and corporate governance
The board is divided into three staggered classes, each serving three-year terms.
Nominees for Class I directors: Howard Mayer, Joshua Resnick, and Lisa Wyman, all with significant industry experience.
Board committees include audit, compensation, and nominating/governance, all composed of independent directors.
The chair and CEO roles are separated to enhance governance.
Annual board and committee self-evaluations are conducted.
Latest events from PepGen
- Net loss narrowed as R&D spending declined; cash runway extends into Q4 2027.PEPG
Q2 2026 - PGN-EDODM1 delivers robust splicing correction and favorable safety in DM1 trials.PEPG
Company presentation - DM1 trials achieved record splicing gains and strong safety, with pivotal data due Q1 next year.PEPG
Stifel 2025 Healthcare Conference - Biotech seeks up to $400M in flexible offerings, including $100M ATM sales, to fund R&D and operations.PEPG
Registration filing - PGN-EDODM1 delivers strong splicing correction and safety in DM1, with pivotal data ahead.PEPG
Company presentation - Executive agreements updated and FREEDOM2 trial advanced, with cash runway into 2H 2027.PEPG
Q1 2026 - Virtual meeting to elect directors and ratify KPMG LLP as auditor, with board support for both.PEPG
Proxy filing - PGN-EDODM1 shows strong efficacy and safety in DM1, with pivotal data expected by 2027.PEPG
Company presentation - PGN-EDODM1 at 5 mg/kg showed strong safety and splicing correction, supporting dose escalation.PEPG
Study update